Stay updated on Eli Lilly and Company Press Releases
Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F48YTu8MinYZKrfgYinJnFkK_j9c.uncropped.jpg&w=3840&q=75)
Latest updates to the Eli Lilly and Company Press Releases page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedEli Lilly has launched Zepbound® (tirzepatide) single-dose vials, significantly reducing costs for obesity treatment, while also announcing participation in the upcoming Morgan Stanley Global Healthcare Conference.SummaryDifference100%
- Check18 days agoChange DetectedEli Lilly announced significant advancements with tirzepatide, showing a 94% reduction in type 2 diabetes risk for adults with pre-diabetes and obesity, alongside a 22.9% average weight loss in a 176-week study, while also completing the acquisition of Morphic to enhance its immunology pipeline.SummaryDifference100%
- Check25 days agoChange DetectedLilly has opened a new 346,000 square foot research and development center in the Boston Seaport, enhancing its genetic medicines efforts, while also reporting a significant 36% revenue increase in Q2 2024, raising its full-year revenue guidance by $3 billion.SummaryDifference100%
- Check32 days agoChange DetectedLilly's tirzepatide has shown promising results in a phase 3 study for adults with heart failure and obesity, significantly reducing heart failure outcomes by 38% compared to placebo, while the company has also seen the departure of its CFO, Anat Ashkenazi.SummaryDifference14%
- Check44 days agoChange DetectedEli Lilly has announced the date for its second-quarter 2024 financial results and a conference call on August 8, 2024, while the previous announcement regarding Melissa Seymour joining as executive vice president of Global Quality has been removed.SummaryDifference14%
- Check61 days agoChange DetectedLilly has announced the acquisition of Morphic to enhance outcomes for patients with Inflammatory Bowel Disease by expanding their immunology pipeline with oral integrin therapies.SummaryDifference15%
Stay in the know with updates to Eli Lilly and Company Press Releases
Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.